A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

NCT01830985 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vertex Pharmaceuticals Incorporated